Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

被引：0
|
作者：
Sanne Bootsma
Sanne M. van Neerven
Louis Vermeulen
机构：
[1] Amsterdam University Medical Centers,Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism
[2] Oncode Institute Amsterdam,undefined
来源：
Nature Genetics | 2021年 / 53卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.
引用
收藏
页码：9 / 10
页数：1
相关论文
共 50 条
  • [31] Inflammation-Induced Metabolic Reprogramming in Chondrocytes is a Therapeutic Target in Joint Disease
    Arra, Manoj
    Swarnkar, Gaurav
    O'Keefe, Regis
    Shen, Jie
    Abu-Amer, Yousef
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 202 - 202
  • [32] Erratum: Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
    H Yurugi
    F Marini
    C Weber
    K David
    Q Zhao
    H Binder
    L Désaubry
    K Rajalingam
    Oncogene, 2017, 36 : 5914 - 5914
  • [33] Targeting metabolic reprogramming in KRAS-driven cancers
    Kawada, Kenji
    Toda, Kosuke
    Sakai, Yoshiharu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (04) : 651 - 659
  • [34] Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer
    Nawab Azizi
    Jelena Toma
    Mickenzie Martin
    Muhammad Faran Khalid
    Fatemeh Mousavi
    Phyo Wei Win
    Maria Teresa Borrello
    Nina Steele
    Jiaqi Shi
    Marina Pasca di Magliano
    Christopher L. Pin
    Oncogene, 2021, 40 : 3118 - 3135
  • [35] Targeting metabolic reprogramming in KRAS-driven cancers
    Kenji Kawada
    Kosuke Toda
    Yoshiharu Sakai
    International Journal of Clinical Oncology, 2017, 22 : 651 - 659
  • [36] The role of PP2A-B56α in KRAS-mediated pancreatic tumorigenesis.
    Tinsley, Samantha L.
    Shelley, Rebecca A.
    Mall, Gagan K.
    Chianis, Ella Rose D.
    Thoma, Mary C.
    di Magliano, Marina Pasca
    Narla, Goutham
    Sears, Rosalie C.
    Allen-Petersen, Brittany L.
    CANCER RESEARCH, 2022, 82 (22) : 101 - 102
  • [37] Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation
    Wu, Bo-Kuan
    Brenner, Charles
    CELL REPORTS, 2014, 9 (05): : 1827 - 1840
  • [38] HIF-1 mediated metabolic reprogramming in cancer: Mechanisms and therapeutic implications
    Taneja, Nikita
    Chauhan, Akansha
    Kulshreshtha, Ritu
    Singh, Sandhya
    LIFE SCIENCES, 2024, 352
  • [39] Targeting Txnip-mediated metabolic reprogramming has therapeutic potential for osteoarthritis
    Cao, Xiankun
    Yang, Xiao
    Zhang, Pu
    Xu, Jianguang
    Zhao, Jie
    Yang, Erzhu
    CELL DEATH DISCOVERY, 2025, 11 (01)
  • [40] Exploring the role of mutant Kras-mediated inflammation in endometriosis development using murine models
    Wu, Shin-Ting
    Tsai, Eing-Mei
    Suen, Jau-Ling
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1611 - 1611
12345